Triomics secures $22 million Series B to expand oncology AI platform
The company reports a tenfold rise in annualised recurring revenue as it scales its specialised models for clinical trial matching and regulatory reporting.
Triomics, a startup developing an artificial intelligence platform to automate administrative workflows for oncologists, has secured $22 million in Series B funding. The round was led by Battery Ventures, with participation from returning investors Nexus Venture Partners, Lightspeed, and Y Combinator. The capital will support the expansion of the company’s oncology-specific models, which assist with clinical trial matching, patient summarisation, and regulatory reporting.
Founded in 2021, Triomics initially focused on helping clinicians identify suitable clinical trials for patients. As large language model capabilities evolved, the platform expanded to address the growing complexity of medical records. Co-founder Sarim Khan noted that oncology breakthroughs are keeping patients alive longer, resulting in dense, multi-year medical charts that can contain thousands of pages of physician notes, imaging reports, and pathology data.
The platform utilises models trained specifically on oncology data to navigate this complexity. Over the past couple of years, Triomics has integrated verifiable patient summaries directly into existing clinical tools, allowing doctors to review key information without switching applications. This functionality is designed to reduce appointment preparation time, addressing staff burnout and allowing oncologists to dedicate more time to patient care.
Triomics also automates the submission of tumour reports to government registries, a legal requirement for cancer centres. While competitors such as Abridge and Microsoft’s Nuance focus on documenting patient-doctor conversations, Triomics differentiates itself through its specialised training data. Prominent institutions, including Memorial Sloan Kettering and Yale Cancer Center, currently utilise the platform for its ability to handle the unique demands of oncology records.
The funding follows a $15 million Series A raise in mid-2024. According to Khan, the company has seen its enterprise customer base expand fourfold over the past 12 months, driving a tenfold increase in annualised recurring revenue. The new investment positions Triomics to further scale its operations within the healthcare technology sector.
